Population
Patients with type 2 diabetes and preclinical models
Design
Review
Authors
Loading...
Supports linagliptin in T2D with renal impairment without adjustment; leaves open whether preclinical pleiotropic effects confer clinical benefit.
Linagliptin is an effective DPP-4 inhibitor for glycemic control in type 2 diabetes that does not require renal dose adjustment and may have additional pleiotropic benefits.
John Doupis (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: